AIMN Multicenter Study: Staging of Lymphomas Using PET/CT

Lymphoma Clinical Trial

Official title:

AIMN Multicenter Study: Staging of Lymphomas Using PET/CT

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06179693
• Other study ID #: 34/2008/O/OSS
• Status: Completed
• Start date: October 7, 2009
• Est. completion date: February 24, 2011

Study information

• Verified date: December 2023
• Source: IRCCS San Raffaele
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In recent years, the introduction of PET/CT tomographs (which have now almost completely replaced tomographs equipped with PET alone), has allowed a significant increase in diagnostic accuracy in the majority of tumors. However, in order to reduce the radiation doses, administering CT images are acquired for patients at a low dose (generally 60mA 120kV) without the use of contrast agents. This prudential attitude, however, makes it essential to carry out "diagnostic" CT investigations which, at the end of the diagnostic process It leads to an increase in the dose administered for the patient rather than to savings.

This study aims to evaluate the possible advantages in diagnostic, economic and quality of life terms of PET/CT performed with diagnostic CT with intravenous contrast medium, with the aim of benefiting the neoplastic patient in the diagnostic process by optimizing (from a temporal and dosimetric point of view ) the diagnostic procedures to which it is subjected.

It is expected that the integrated PET/CT procedure can facilitate the process of staging the neoplasm and that this procedure can have a positive impact on the patient's quality of life while also reducing the costs incurred in terms of time and money.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: February 24, 2011
• Est. primary completion date: February 24, 2011
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Established lymphoma (non-Hodgkin's lymphoma and Hodgkin's disease) being staged;

• Performing the PET/CT examination within two weeks of diagnosis and before treatment;

• Signing of the Informed Consent.

Exclusion Criteria:

• patients <18 years;

• Patients who have not signed the Informed Consent;

• Execution of previous anti-inflammatory or anti-inflammatory therapies in the 4 weeks preceding the PET exam.

Related Conditions & MeSH terms

• Lymphoma

Intervention

Diagnostic Test:
• Diagnostic accuracy
As per standard procedure, patients will undergo FDG PET. Following the PET exam it will be acquired a standard CT with intravenous contrast medium, using the CT tomograph inserted inside the PET one.

Locations

Country	Name	City	State
Italy	Irccs San Raffaele	Milano

Sponsors (1)

Lead Sponsor	Collaborator
IRCCS San Raffaele

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PET/CT with contrast medium in a single session to diagnosis of patients with malignant limphoma.		2 years